ADVANCED INSTRUMENTS acquired by PATRICIA INDUSTRIES

Ardian Growth acquired a minority stake in H2 Pharma in its inaugural healthcare investment. The partnership was established to support the company's ambitious industrial scaling, with a production target of 100 million units per year. The strategic roadmap focuses on internationalizing the group's footprint within the European market and diversifying its service offering to include regulatory affairs and analytical control. Ardian provides strategic support to leverage H2 Pharma's automated manufacturing processes and R&D capabilities, aiming to strengthen its position as a preferred CDMO partner for international pharmaceutical laboratories

Sulzer has completed the acquisition of Haselmeier, integrating the drug delivery specialist into its Applicator Systems (APS) division. The transaction was structured to acquire 100% of the privately held Swiss-German company, allowing Sulzer to immediately scale its healthcare business and leverage Haselmeier’s significant portfolio of proprietary intellectual property.The strategic rationale for this acquisition is centered on technical synergy and market expansion. By combining Haselmeier’s competence in self-injection devices with Sulzer’s existing expertise in precision injection molding and liquid mixing, the group intends to accelerate the development of innovative and differentiated medical devices

Permira acquired Neuraxpharm from Apax Partners, following a competitive auction process. The transaction was structured to support the company's transition from a regional player to a pan-European leader. Under Permira's ownership, the management team led by CEO Dr. Dierks remained in place to execute a high-velocity buy-and-build strategy. The deal was financed through a combination of equity and a significant leveraged loan package, aiming to capitalize on the resilient and growing market for CNS treatments

EQT completed the acquisition of 100% of Schülke from its parent company, Air Liquide. This transaction represents a strategic carve-out for Air Liquide, allowing the French industrial gas giant to refocus on its core activities while providing Schülke with the independent capital necessary for long-term expansion. Announced during the height of the COVID-19 pandemic, the deal saw increased competition from other major private equity firms (PAI Partners, Ardian) due to Schülke’s critical role in infection prevention

The acquisition of Vision Healthcare NV by Avista Capital Partners marks a significant milestone in the company's strategic journey. The partnership enables Vision to realize further rapid growth and make additional investments that leverage its differentiated direct-to-consumer business model. With Avista's expertise and resources, Vision is well-positioned to expand its geographic reach and accelerate its acquisition strategy into the global direct-to-consumer healthcare market. The transaction also allows Vision to benefit from Avista's experience in the consumer healthcare sector, providing operational guidance and financial resources to drive growth and performance

The divestiture of the Life Sciences division by NN inc. (Paragon Medical) to American Securities represents a pivotal structural transformation for both organizations. For the seller, the transaction provides a necessary capital infusion to significantly reduce corporate debt and reposition its remaining industrial platform toward power and mobile solutions. The strategic rationale for the move centers on the acquirer’s objective to combine the division’s high-precision surgical capabilities with its existing portfolio company, MW Industries, thereby creating a comprehensive engineering powerhouse for specialized fasteners and medical components

Royal DSM reached an agreement to acquire 100% of Glycom A/S. The strategic rationale for the acquisition is to accelerate DSM’s growth in the Early Life Nutrition (ELN) segment by adding HMOs (a novel, high-growth ingredient) to its portfolio. DSM intends to leverage its global sales force to offer Glycom’s HMOs to its broad customer base, reducing Glycom’s historical dependency on a single major customer (Nestlé). Furthermore, DSM aims to utilize its R&D and clinical competencies to speed up the development of next-generation HMOs and introduce these ingredients into new markets such as medical nutrition and pet food

Warburg Pincus has acquired a 50% co-control stake in Polyplus from ArchiMed, executing a flagship LBO in the European mid-cap space. The transaction structure is characterized by a significant reinvestment from the incumbent sponsor, ArchiMed, ensuring that both private equity firms hold equal equity stakes and voting rights post-closing. To finance this acquisition, a bespoke unitranche debt facility was arranged and provided by Tikehau Capital and Goldman Sachs. The definitive agreement was signed following supreme execution certainty and intense competitive tension prior to the pandemic-induced market slowdown

LBO France acquired a controlling stake in Dutscher, replacing Five Arrows (who had held the majority since 2014). This Secondary LBO also marked the exit of the founder's son, who held ~40% but had no operational role, completing the transition from a family-owned business to a financial-backed platform.

The acquisition of the High Ridge Brands Oral Care assets by Perrigo signifies a definitive densification of the group’s specialized hygiene division. The strategic rationale for this transaction hinges on a "category-dominance" maneuver, merging the target’s technical operational depth in the branded-value children’s segment with the acquirer’s massive Ranir platform. This structural alignment provides the organization with the scientific talent and trademark hardware necessary to address the increasing consumer shift toward high-quality, cost-effective oral health solutions